retatrutide phase 2 trial obesity nejm 2023 triple agonist

retatrutide phase 2 trial obesity nejm 2023 triple agonist Michael Weintraub, MD on X: "Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Retatrutide Weight Loss Results |

Name: retatrutide phase 2 trial obesity nejm 2023 triple agonist Michael Weintraub, MD on X: "Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Retatrutide Weight Loss Results |
Brand: actil.am
SKU: 51655139645
Price: 29.40 USD
Availability: InStock
Rating: 4.8487 (19 reviews)

SKU: 51655139645

4.8

USD29.40 USD52.40

Pay in 4 interest-free payments of $7.35 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 24 - Aug 29

Description

At the moment, Mounjaro is a diabetes drug, but Pisano said that the FDA is currently examining data on whether to include it in the weight loss class, and that decision might come in October